A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects With Neutropenia

Trial Profile

A Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous (IV) and Powder for Oral Suspension Formulations of Posaconazole (POS) in Immunocompromised Pediatric Subjects With Neutropenia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Posaconazole (Primary) ; Posaconazole (Primary)
  • Indications Neutropenia
  • Focus Pharmacokinetics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 15 May 2017 Treatment arm has been increases from 4 to 6 (6 mg/kg dose of POS has added) and patients number also increases.
    • 15 May 2017 Planned number of patients changed from 60 to 84.
    • 26 Aug 2016 Planned End Date changed from 1 Apr 2017 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top